BiondVax Pharmaceuticals Ltd.
BVXVW
BVXVW was delisted on the 13th of May, 2020.
2 hedge funds and large institutions have $124K invested in BiondVax Pharmaceuticals Ltd. in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
288% more capital invested
Capital invested by funds: $32K → $124K (+$92K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $107K | – | – | – |
|
|
VIA
2
Vantage Investment Advisors
State College,
Pennsylvania
| $17K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$1K | -2,001 | Closed |
|
BVXVW Hedge Fund Activity: Q1 2017 in Review
2 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in BiondVax Pharmaceuticals Ltd. (BVXVW) for Q1 2017, worth a combined $124K — up 288% from $32K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BVXVW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $1K sold.
- 2 institutional investors held BiondVax Pharmaceuticals Ltd. (BVXVW) as of Q1 2017, down from 3 in Q4 2016.
- Funds reported $124K of BiondVax Pharmaceuticals Ltd. stock for Q1 2017, up 288% quarter-over-quarter.
- 0 funds opened new BiondVax Pharmaceuticals Ltd. positions in Q1 2017 and 1 closed out, a net change of -1 holder.
- The largest BiondVax Pharmaceuticals Ltd. seller in Q1 2017 was UBS Group, an estimated $1K sold.
Based on aggregated 13F filings for Q1 2017.